Gemigliptin/glimepiride

Drug Profile

Gemigliptin/glimepiride

Alternative Names: Glimepiride/gemigliptin; ZemiSU

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2015 Gemigliptin/glimepiride is still in phase I trials for Type-2 diabetes mellitus in South Korea
  • 02 Apr 2014 LG Life Sciences plans a phase III trial for Type-2 diabetes mellitus in South Korea (NCT02089126)
  • 01 Apr 2013 LG Life Sciences completes a phase I pharmacokinetic drug interaction trial in healthy volunteers in South Korea (NCT01768455)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top